000295833 001__ 295833
000295833 005__ 20241215014415.0
000295833 0247_ $$2doi$$a10.3238/arztebl.m2024.0151
000295833 0247_ $$2pmid$$apmid:39158357
000295833 0247_ $$2altmetric$$aaltmetric:167031362
000295833 037__ $$aDKFZ-2024-02653
000295833 041__ $$aEnglish
000295833 082__ $$a610
000295833 1001_ $$aBamberg, Fabian$$b0
000295833 245__ $$aBaseline MRI Examination in the NAKO Health Study—Findings on Feasibility, Participation and Dropout Rates, Comfort, and Image Quality.
000295833 260__ $$aKöln$$bDt. Ärzte-Verl.$$c2024
000295833 3367_ $$2DRIVER$$aarticle
000295833 3367_ $$2DataCite$$aOutput Types/Journal article
000295833 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1734014734_9063
000295833 3367_ $$2BibTeX$$aARTICLE
000295833 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000295833 3367_ $$00$$2EndNote$$aJournal Article
000295833 520__ $$aMagnetic resonance imaging (MRI) yields important information on the development and current status of many different diseases. Whole-body MRI was accordingly made a part of the multicenter, population-based NAKO Health Study. The present analysis concerns the feasibility of the baseline MRI examination and various aspects of quality assurance over the period 2014-2019.32 252 participants in the NAKO Health Study, aged 20 to 74, who had no contraindication to MRI were invited to undergo scanning in one of five MRI study centers across Germany. The whole-body MRI scan took about one hour and consisted of sequences for the visualization of structural and functional features of the brain, musculoskeletal system, cardiovascular system, and thoracoabdominal system. A comprehensive quality-assurance assessment was carried out, with evaluation of adverse events, the completeness of the MRI protocols, the participants' subjective perceptions, and image quality.31 578 participants (97.9%) were successfully included in the MRI study. They reported a high level of comfort and suffered no severe adverse events (mild adverse events occurred in only four participants). Depending on the imaging sequence, the image quality was rated as excellent in 80.2% to 96.8% of cases. Quality assessment with respect to structural features of the brain revealed high consistency across study centers, as well as with regard to age- and sex-based differences in brain volume (men, 1203.81 ± 102.06 cm³; women, 1068.10 ± 86.69 cm³).Whole-body MRI was successfully implemented in the NAKO baseline examination and was associated with high patient comfort and very good image quality. The imaging biomarkers of the brain confirmed previously observed differences based on age and sex, underscoring the feasibility of data pooling.
000295833 536__ $$0G:(DE-HGF)POF4-313$$a313 - Krebsrisikofaktoren und Prävention (POF4-313)$$cPOF4-313$$fPOF IV$$x0
000295833 588__ $$aDataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
000295833 650_2 $$2MeSH$$aHumans
000295833 650_2 $$2MeSH$$aMagnetic Resonance Imaging: methods
000295833 650_2 $$2MeSH$$aFemale
000295833 650_2 $$2MeSH$$aMale
000295833 650_2 $$2MeSH$$aAdult
000295833 650_2 $$2MeSH$$aMiddle Aged
000295833 650_2 $$2MeSH$$aGermany
000295833 650_2 $$2MeSH$$aFeasibility Studies
000295833 650_2 $$2MeSH$$aAged
000295833 650_2 $$2MeSH$$aYoung Adult
000295833 650_2 $$2MeSH$$aWhole Body Imaging: methods
000295833 7001_ $$aSchlett, Christopher L$$b1
000295833 7001_ $$aCaspers, Svenja$$b2
000295833 7001_ $$aRinghof, Steffen$$b3
000295833 7001_ $$aGünther, Matthias$$b4
000295833 7001_ $$aHirsch, Jochen G$$b5
000295833 7001_ $$aRüdebusch, Julia$$b6
000295833 7001_ $$aMiklánková, Pavlína$$b7
000295833 7001_ $$aBittner, Nora$$b8
000295833 7001_ $$aJockwitz, Christiane$$b9
000295833 7001_ $$aForsting, Michael$$b10
000295833 7001_ $$aHosten, Norbert$$b11
000295833 7001_ $$0P:(DE-HGF)0$$aKaaks, Rudolph$$b12
000295833 7001_ $$aKauczor, Hans-Ulrich$$b13
000295833 7001_ $$aKroenke, Thomas$$b14
000295833 7001_ $$aNiendorf, Thoralf$$b15
000295833 7001_ $$aPeters, Annette$$b16
000295833 7001_ $$aPischon, Tobias$$b17
000295833 7001_ $$aStang, Andreas$$b18
000295833 7001_ $$aBerger, Klaus$$b19
000295833 7001_ $$aVölzke, Henry$$b20
000295833 7001_ $$0P:(DE-HGF)0$$aConsortium, NAKO Investigators$$b21
000295833 773__ $$0PERI:(DE-600)2406159-1$$a10.3238/arztebl.m2024.0151$$gVol. 121, no. 18$$n18$$p587-593$$tDeutsches Ärzteblatt international$$v121$$x1866-0452$$y2024
000295833 909CO $$ooai:inrepo02.dkfz.de:295833$$pVDB
000295833 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-HGF)0$$aDeutsches Krebsforschungszentrum$$b12$$kDKFZ
000295833 9131_ $$0G:(DE-HGF)POF4-313$$1G:(DE-HGF)POF4-310$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vKrebsrisikofaktoren und Prävention$$x0
000295833 9141_ $$y2024
000295833 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bDTSCH ARZTEBL INT : 2022$$d2023-08-19
000295833 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2023-08-19
000295833 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2023-08-19
000295833 915__ $$0StatID:(DE-HGF)0320$$2StatID$$aDBCoverage$$bPubMed Central$$d2023-08-19
000295833 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2023-08-19
000295833 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2023-08-19
000295833 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2023-08-19
000295833 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2023-08-19
000295833 915__ $$0StatID:(DE-HGF)9905$$2StatID$$aIF >= 5$$bDTSCH ARZTEBL INT : 2022$$d2023-08-19
000295833 9201_ $$0I:(DE-He78)C020-20160331$$kC020$$lC020 Epidemiologie von Krebs$$x0
000295833 980__ $$ajournal
000295833 980__ $$aVDB
000295833 980__ $$aI:(DE-He78)C020-20160331
000295833 980__ $$aUNRESTRICTED